J. Trad Wadsworth

Dr. J. Trad Wadsworth

Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2020 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
JIJanis V. de la Iglesia
Janis V. de la Iglesia
RSRobbert J.C. Slebos
Robbert J.C. Slebos
LMLaura Martin-Gomez
Laura Martin-Gomez
XWXuefeng Wang
Xuefeng Wang
JTJamie K. Teer
Jamie K. Teer
CCChristine Chung
Christine Chung
Purpose: Patients with head and neck squamous cell carcinoma (HNSCC) who actively smoke during treatment have worse survival compared with never-smokers and former-smokers. We hypothesize the poor prognosis in tobacco smokers with HNSCC is, at least in part, due to ongoing suppression of immune response. We characterized the tumor immune microenvironment (TIM) of HNSCC in a retrospective cohort of 177 current, former, and never smokers. Experimental Design: Tumor specimens were subjected to analysis of CD3, CD8, FOXP3, PD-1, PD-L1, and pancytokeratin by multiplex immunofluorescence, whole-exome sequencing, and RNA sequencing. Immune markers were measured in tumor core, tumor margin, and stroma. Results: Our data indicate that current smokers have significantly lower numbers of CD8+ cytotoxic T cells and PD-L1+ cells in the TIM compared with never- and former-smokers. While tumor mutation burden and mutant allele tumor heterogeneity score do not associate with smoking status, gene-set enrichment analyses reveal significant suppression of IFNα and IFNγ response pathways in current smokers. Gene expression of canonical IFN response chemokines, CXCL9, CXCL10, and CXCL11, are lower in current smokers than in former smokers, suggesting a mechanism for the decreased immune cell migration to tumor sites. Conclusions: These results suggest active tobacco use in HNSCC has an immunosuppressive effect through inhibition of tumor infiltration of cytotoxic T cells, likely as a result of suppression of IFN response pathways. Our study highlights the importance of understanding the interaction between smoking and TIM in light of emerging immune modulators for cancer management.

9 March 2021 in Cancers
Verified
Journal Article
Open access
PDF file
CCChristine Chung
Christine Chung
MBMarcelo Bonomi
Marcelo Bonomi
CSConor E. Steuer
Conor E. Steuer
JLJiannong Li
Jiannong Li
PBPriyanka Bhateja
Priyanka Bhateja
Nabil SabaNabil Saba
Nabil Saba
We hypothesized the combination of cetuximab and nivolumab would improve survival in recurrent and/or metastatic (R/M) HNSCC by providing synergy in cancer control and evaluated toxicities and efficacy of the combination. Effects of sequential administration of cetuximab and anti-Programmed Cell Death-1 checkpoint inhibitors (CPI) were also explored. Patients who failed at least one line of palliative treatment for incurable HNSCC were treated with cetuximab 500 mg/m2 IV on Day (D)-14 as a lead-in followed by cetuximab 500 mg/m2 IV and nivolumab 240 mg/m2 IV on D1 and D15 every 28-D cycle. Electronic health record-derived real-world data (RWD) were used to explore sequential treatment effects of CPI and cetuximab. A total of 45 evaluable patients were analyzed, and 31/45 (69%) patients had prior exposure to either CPI or cetuximab. The only grade 4 treatment-related adverse event was cetuximab infusion reaction in one patient. The 1-year progression-free survival (PFS) and overall survival (OS) rates were 19% and 44%, respectively. Although patients with no prior CPI (23/45, 51%) showed a trend for more favorable PFS relative to patients with prior CPI (22/45, 49%), the improvement in the 1-year OS did not reach the statistical threshold. For evaluation of sequential CPI and cetuximab treatment effects, we selected RWD-cetuximab cohort with 173 patients and RWD-CPI cohort with 658 patients from 6862 R/M HNSCC. Our result suggested patients treated with RWD-cetuximab after RWD-CPI had worse OS compared to no prior RWD-CPI (HR 1.81, 95% CI 1.02–3.16). Our data suggest the combination of cetuximab and nivolumab is well tolerated. Optimal sequencing of cetuximab and CPI may have an impact in prognosis and requires further evaluation.

1 October 2017 in Thyroid®
Verified
Journal Article
Closed access
PVPablo Valderrabano
Pablo Valderrabano
LKLaila Khazai
Laila Khazai
ZTZachary Thompson
Zachary Thompson
MLMarino E. Leon
Marino E. Leon
KOKristen J. Otto
Kristen J. Otto
BMBryan McIver
Bryan McIver
Background: Management recommendations for thyroid nodules rely primarily on the cytological diagnosis. However, 25% of biopsies render an indeterminate cytology for which management decision is more challenging due to heterogeneity of the specimens. This study aimed to stratify the cancer risk through subcategorization of indeterminate cytology. Methods: The indeterminate cytological specimens (Bethesda-III or IV) of 518 thyroid nodules consecutively evaluated at our academic cancer center between October 2008 and September 2015, blinded to the histological outcome, were retrospectively reviewed. Cytological specimens were subclassified into four groups: aspirates exhibiting nuclear atypia ( n = 158; 31%); architectural atypia ( n = 222; 43%); oncocytic features ( n = 120; 23%); or other types of atypia ( n = 18; 3%). The prevalence of malignancy and odds ratio for malignancy were calculated in 323 nodules with histological confirmation. Results: The prevalence of malignancy was 26% overall (20% in Bethesda-III and 29% in Bethesda-IV; p = 0.07), and 47%, 12%, 24%, and 25% for aspirates with nuclear atypia, architectural atypia, oncocytic features, or other types of atypia, respectively. The OR of nuclear atypia over architectural atypia was 6.4 (3.4–12.2; p < 0.001), and 2.7 over oncocytic features (1.4–5.1; p = 0.01), whereas the OR of architectural atypia over oncocytic features was 0.4 (0.2–0.9; p = 0.03). Results were similar for Bethesda-III and IV aspirates when analyzed independently. Furthermore, cytological subcategories improved cytology–histology correlation, as they were associated with distinct profiles of histological diagnoses ( p < 0.001). Conclusions: Cytological subcategories can effectively stratify the risk of malignancy of thyroid nodules with indeterminate cytology and improve cytology–histology correlation.

6 April 2018 in Head & Neck
Verified
Journal Article
Closed access
PDF file
PVPablo Valderrabano
Pablo Valderrabano
LKLaila Khazai
Laila Khazai
ZTZachary J. Thompson
Zachary J. Thompson
MLMarino E. Leon
Marino E. Leon
KOKristen J. Otto
Kristen J. Otto
BMBryan McIver
Bryan McIver

10 November 2016 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
JJJ.C. Junn
J.C. Junn
KBK.L. Baugnon
K.L. Baugnon
ELE.A. Lacayo
E.A. Lacayo
PHP.A. Hudgins
P.A. Hudgins
MPM.R. Patel
M.R. Patel
AAA.H. Aiken
A.H. Aiken
BACKGROUND AND PURPOSE: Extrinsic tongue muscle invasion in oral cavity cancer upstages the primary tumor to a T4a. Despite this American Joint Committee on Cancer staging criterion, no studies have investigated the accuracy or prognostic importance of radiologic extrinsic tongue muscle invasion, the feasibility of standardizing extrinsic tongue muscle invasion reporting, or the degree of agreement across different disciplines: radiology, surgery, and pathology. The purpose of this study was to assess the agreement among radiology, surgery, and pathology for extrinsic tongue muscle invasion and to determine the imaging features most predictive of extrinsic tongue muscle invasion with surgical/pathologic confirmation. MATERIALS AND METHODS: Thirty-three patients with untreated primary oral cavity cancer were included. Two head and neck radiologists, 3 otolaryngologists, and 1 pathologist prospectively evaluated extrinsic tongue muscle invasion. RESULTS: Fourteen of 33 patients had radiologic extrinsic tongue muscle invasion; however, only 8 extrinsic tongue muscle invasions were confirmed intraoperatively. Pathologists were unable to determine extrinsic tongue muscle invasion in post-formalin-fixed samples. Radiologic extrinsic tongue muscle invasion had 100% sensitivity, 76% specificity, 57% positive predictive value, and 100% negative predictive value with concurrent surgical-pathologic evaluation of extrinsic tongue muscle invasion as the criterion standard. On further evaluation, the imaging characteristic most consistent with surgical-pathologic evaluation positive for extrinsic tongue muscle invasion was masslike enhancement. CONCLUSIONS: Evaluation of extrinsic tongue muscle invasion is a subjective finding for all 3 disciplines. For radiology, masslike enhancement of extrinsic tongue muscle invasion most consistently corresponded to concurrent surgery/pathology evaluation positive for extrinsic tongue muscle invasion. Intraoperative surgical and pathologic evaluation should be encouraged to verify radiologic extrinsic tongue muscle invasion to minimize unnecessary upstaging. Because this process is not routine, imaging can add value by identifying those cases most suspicious for extrinsic tongue muscle invasion, thereby prompting this more detailed evaluation by surgeons and pathologists.

8 April 2012 in Head & Neck
Verified
Journal Article
Closed access
PDF file
SKSvetlana S. Kats
Svetlana S. Kats
SMSusan Muller
Susan Muller
AAAshley Aiken
Ashley Aiken
PHPatricia A. Hudgins
Patricia A. Hudgins
J. Trad WadsworthJ. Trad Wadsworth
J. Trad Wadsworth
JBJonathan J. Beitler
Jonathan J. Beitler